TOKYO (Bloomberg): Japanese drugmaker Shionogi & Co. Ltd. said the Covid-19 pill it’s developing could be a US$2 billion drug potentially used in combination with a similar offering from Merck & Co Inc, as the pandemic’s focus shifts to the need for easy-to-take medications able to combat mild cases.
Shionogi expects to have late-stage trial data for its pill by December and will move quickly on filing for regulatory approval in Japan, chief executive officer Isao Teshirogi told Bloomberg in an interview.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
